AVECTAS LIMITED

Their core work

Avectas is an Irish biotechnology SME specialising in intracellular delivery technology for cell and gene therapy manufacturing. Their flagship platform, Solupore®, is a proprietary method for loading therapeutic cargo into cells — addressing a critical bottleneck in producing affordable cancer treatments such as CAR-T cell therapies. Beyond their own product, they contribute to the broader biopharmaceutical field through collaborative research on upstream bioprocess development, covering gene therapy, viral vectors (including oncolytic viruses), vaccines, and therapeutic proteins. They bridge the gap between laboratory-scale research and scalable, cost-effective clinical manufacturing.

What they specialise in

How they've shifted over time

Avectas entered H2020 as a technology developer with a single proprietary platform (Solupore®), focused on proving commercial viability for cancer treatment manufacturing through the SME Instrument Phase 2. Their second project, STACCATO, marks a shift toward embedding in the broader biopharmaceutical research ecosystem — participating in an Industrial Doctorate training network signals a move from product validation toward talent development and upstream process knowledge. The absence of early-period keywords and the concentration of all technical terms in the recent period reflects a company that used EU funding first to commercialise, then to deepen scientific roots and expand into adjacent therapy modalities.

Avectas appears to be expanding from a single-platform SME into a broader biopharma manufacturing partner — their involvement in MSCA doctoral training suggests growing ambitions to contribute to next-generation cell, gene, and viral vector therapy pipelines beyond their own product.

How they like to work

Avectas has acted as both project coordinator and consortium partner, which is unusual for a small SME with only two projects — it shows strategic versatility rather than passive participation. As coordinator of SOLUPORE they led a focused development project, while as partner in STACCATO they joined a large multi-country training network, suggesting they can adapt their role to fit the collaboration's needs. With 15 unique partners across 7 countries for just two projects, they engage broad, diverse consortia rather than relying on a fixed inner circle.

Avectas has built a surprisingly wide network for a two-project SME — 15 unique consortium partners across 7 countries, likely spanning academic institutions, biopharma companies, and clinical partners through the STACCATO network. Their geographic reach extends well beyond Ireland into core European biopharma hubs.

What sets them apart

Avectas stands out as one of very few Irish SMEs with a proprietary intracellular delivery platform (Solupore®) validated through a competitive SME Instrument Phase 2 award — a grant that funds fewer than 5% of applicants — which signals both technological credibility and commercial readiness. They occupy a rare position as a technology provider in cell and gene therapy manufacturing, a sector where most EU H2020 participants are academic or large pharma. For consortium builders, they bring both a concrete enabling technology and hands-on manufacturing process expertise that is difficult to find in a single SME partner.

Highlights from their portfolio

• SOLUPORE
  Coordinator role with €2.09M EC funding under the highly competitive SME Instrument Phase 2, built around Avectas's own proprietary cell loading technology for cancer treatment manufacturing — rare for a small Irish biotech.
• STACCATO
  Participation in a Marie Skłodowska-Curie Industrial Doctorate network demonstrates Avectas's standing as an industry training host in European biopharmaceutical research, extending their influence into PhD-level talent development.